Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1Phase 2 1

Status

Completed 7Unknown 4Terminated 4Recruiting 3Active not recruiting 3

Sponsor Class

OTHER 4OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Head & Neck 4Endocrine 1

Conditions

Thyroid Neoplasms 3Thyroid Cancer, Papillary 1

Interventions

Cisplatin 352Oxaliplatin 262Capecitabine 258Radiotherapy 240Gemcitabine 223Docetaxel 223Carboplatin 223Cyclophosphamide 219Drug Therapy 218Paclitaxel 205apatinib 201Bevacizumab 195camrelizumab 190Fluorouracil 187sintilimab 133Blood Specimen Collection 125Irinotecan 124Dexamethasone 123Etoposide 119Radiosurgery 118toripalimab 117Surgical Procedures, Operative 115pembrolizumab 110Pemetrexed 108anlotinib 105S 1 (combination) 105Surveys and Questionnaires 101Leucovorin 101Nivolumab 98tislelizumab 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × OTHER × Iodine-131 × Clear all
NCT04354324 2024-03-15

Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma

Zhujiang Hospital

Phase NA Unknown
254 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary

NCT05468554 2022-10-19

METHYR

Medical University of Bialystok

Phase 3 Unknown
160 enrolled
Head & Neck

Thyroid Neoplasms

NCT04952493 2022-01-28

Anlotinib or Penpulimab in Combination With RAI for DTC

Peking Union Medical College Hospital

Phase 2 Unknown
42 enrolled
Head & Neck

Thyroid Neoplasms

NCT00115895 2018-03-02

The Dose of Radioactive Iodine Needed to Ablate the Thyroid Remnant Left Behind After Thyroidectomy

University of Helsinki

Phase 3 Unknown
160 enrolled
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡